{
    "nct_id": "NCT06039384",
    "official_title": "A Phase 1 Study of INCB099280 in Combination With Adagrasib in Adults With Advanced Solid Tumors Harboring a KRASG12C Mutation",
    "inclusion_criteria": "* KRASG12C-mutated solid malignancy determined by a sponsor-approved assay using either tumor tissue or ctDNA.\n* Histologically confirmed malignant solid tumor with locally advanced and/or metastatic disease.\n\n  * Only participants with NSCLC will be enrolled into Part 2 Cohort A.\n  * Only participants with CRC will be enrolled into Part 2 Cohort B.\n* Part 1: Disease progression on or after at least 1 prior systemic treatment.\n* Part 2 (Cohort A - NSCLC): Received an anti-PD-(L)1-containing regimen and platinum based chemotherapy regimen either concurrently or sequentially\n* Part 2 (Cohort B - CRC): Received at least 1 line of systemic therapy that includes the combination of fluoropyrimidine-based chemotherapy (in combination with oxaliplatin and/or irinotecan) and either a vascular endothelial growth factor-targeting monoclonal antibody or an anti-epidermal growth factor receptor monoclonal antibody (if RAS wild type). Participants with MSI-H/dMMR CRC must also have received a prior immune checkpoint inhibitor approved for this indication.\n* Measurable disease according to RECIST v1.1.\n* Eastern Cooperative Oncology Group performance status of 0 or 1.\n* Estimated life expectancy > 3 months.\n* Willingness to avoid pregnancy.\nHealthy volunteers allowed\nMust have minimum age of 18 Years",
    "exclusion_criteria": "* Known additional malignancy that is progressing or requires active treatment.\n* Central nervous system (CNS) metastases requiring treatment and/or leptomeningeal disease.\n* Part 2 only: Prior treatment with an approved or investigational agent targeting KRASG12C.\n* Toxicity from prior therapy that has not recovered to protocol-defined limits.\n* Received thoracic radiation of > 30 Gy within 6 months of the first dose of study treatment.\n* Participation in another interventional clinical study.\n* History or evidence of interstitial lung disease, including noninfectious pneumonitis.\n* Presence of gastrointestinal condition that may affect drug absorption.\n* Active autoimmune disease requiring systemic treatment, including corticosteroids exceeding a daily dose of 10 mg of prednisone or equivalent.\n* Diagnosis of immunodeficiency or receiving chronic systemic steroid therapy exceeding a daily dose of 10 mg of prednisone or equivalent.\n* Active infection requiring systemic therapy.\n* History of organ transplantation, including allogeneic stem cell transplantation.\n* Receipt of systemic antibiotics within 28 days of the first dose of study treatment.\n* Probiotic usage is prohibited during screening and throughout the study treatment period.\n* Received a live vaccine within 28 days of the planned start of study drug.\n* Laboratory values outside the Protocol-defined ranges.\n\nOther protocol-defined Inclusion/Exclusion Criteria may apply.",
    "miscellaneous_criteria": ""
}